Achieve control: a pragmatic clinical trial of insulin glargine 300 U/mL versus other basal insulins in insulin-naïve patients with type 2 diabetes

Oster, Gerry; Sullivan, Sean D.; Dalal, Mehul R.; Kazemi, Mahmood R.; Rojeski, Maria; Wysham, Carol H.; Sung, Jennifer; Johnstone, Bryan; Cali, Anna M.G.; Wei, L.J.; Traylor, Louise; Anhalt, Henry; Hull, Michelle; Van Vleet, John; Meneghini, Luigi F.
November 2016
Postgraduate Medicine;Nov2016, Vol. 128 Issue 8, p731
Academic Journal
journal article
Objective: This study aims to compare the effectiveness of insulin glargine 300 U/mL (Gla-300) with its accompanying patient support program with that of other basal insulin and available patient support programs in patients with type 2 diabetes (T2D) in a real-world setting in terms of achieving HEDIS (Healthcare Effectiveness Data and Information Set) individualized glycemic targets without documented symptomatic hypoglycemia. Methods: Achieve Control is a US-based, multicenter, randomized, open-label, active-controlled, parallel group pragmatic Phase IV trial in insulin-naïve patients with T2D uncontrolled on ≥2 oral antidiabetes drugs (OAD) and/or glucagon-like peptide-1 receptor antagonists (GLP-1 RA). Inclusion criteria include a diagnosis of T2D, age ≥18 years, and glycated hemoglobin (HbA1c) between 8.0% and 11.0%. Patients will be assigned to either the Gla-300 or other basal insulin group. The primary end point is the proportion of patients achieving HEDIS HbA1c targets (<8.0% [64 mmol/mol] in patients with comorbidities or aged ≥65 years; <7.0% [58 mmol/mol] in all other patients) without occurrence of symptomatic hypoglycemia (blood glucose ≤70 mg/dL) from baseline to 6 months. Secondary end points include rates of documented symptomatic nocturnal hypoglycemia and severe hypoglycemia; change from baseline in HbA1c, fasting glucose, and body weight; treatment persistence; patient-reported outcomes; and healthcare resource utilization. Planned enrollment is 3270 patients across approximately 400 clinical sites. Conclusion: Pragmatic clinical trials offer the potential to assess comparative effectiveness in broadly based patient populations receiving care (with or without a corresponding educational support program) in real-world clinical settings. The results of Achieve Control should elucidate the benefits of management of T2D with Gla-300 versus other basal insulins in terms of patient outcomes, experiences, and perceptions, and its impact on healthcare resource utilization and cost. Clinical Trial Registration: www.clinicaltrials.gov identifier is NCT02451137.


Related Articles

  • Glycaemic control with insulin degludec comparable to that with insulin glargine.  // Diabetes Digest;2011, Vol. 10 Issue 3, p151 

    The article discusses a parallel-group phase II trial on the safety and efficacy of insulin degludec (IDec) as compared with once daily (OD) insulin glargine (IGlar) in insulin-naïve type 2 diabetics.

  • Insulin Glargine: An Updated Review of its Use in the Management of Diabetes Mellitus. Dunn, Christopher J.; Plosker, Greg L.; Keating, Gillian M.; McKeage, Kate; Scott, Lesley J. // Drugs;2003, Vol. 63 Issue 16, p1743 

    Insulin glargine is a human insulin analogue prepared by recombinant DNA technology. Modification of the human insulin molecule at position A21 and at the C-terminus of the B-chain results in the formation of a stable compound that is soluble at pH 4.0, but forms amorphous microprecipitates in...

  • Is There a Need for a Better Basal Insulin? Guthrie, Richard // Clinical Diabetes;Spring2001, Vol. 19 Issue 2, p66 

    Discusses the basal insulin therapy, an integral part of intensive management of type 1 diabetes. Goal of diabetes treatment; Limitations of available basal insulins; Structure and function of insulin analogs; Benefits of insulin glargine in pre-clinical glucose clamp studies and in clinical...

  • Defining the Role of Insulin Detemir in Basal Insulin Therapy. Morales, Javier // Drugs;2007, Vol. 67 Issue 17, p2557 

    Insulin detemir is a novel long-acting insulin analogue with a unique mechanism underlying its prolonged duration of action. Unlike neutral protamine Hagedorn (NH) insulin (insulin suspension isophane) and insulin glargine, which precipitate after administration, insulin detemir remains soluble...

  • Insulin Glargine: A Review of its Therapeutic Use as a Long-Acting Agent for the Management of Type 1 and 2 Diabetes Mellitus. McKeage, K.; Goa, K.L. // Drugs;Aug2001, Vol. 61 Issue 11, p1599 

    Insulin glargine is a recombinant human insulin analogue produced by DNA technology using a nonpathogenic strain of Escherichia coli. Two modifications of human insulin result in a stable molecule which is soluble in slightly acidic conditions (pH 4.0) and precipitates in the neutral pH of...

  • Patient safety and minimizing risk with insulin administration - role of insulin degludec. Aye, Myint M.; Atkin, Stephen L. // Drug, Healthcare & Patient Safety;2014, Vol. 6, p55 

    Diabetes is a lifelong condition requiring ongoing medical care and patient self-management. Exogenous insulin therapy is essential in type 1 diabetes and becomes a necessity in patients with longstanding type 2 diabetes who fail to achieve optimal control with lifestyle modification, oral...

  • Insulin detemir "good value for money" for type 1 DM in Austria.  // PharmacoEconomics & Outcomes News;12/17/2005, Issue 493, p7 

    The article discusses the results of a study on the advantage of switching type 1 diabetes mellitus patients to insulin detemir basal-bolus therapy. The improvements in quality-adjusted life expectancy were projected for insulin determir versus insulin glargine. The study found that insulin...

  • The Role of Basal Insulin in TYPE 2 DIABETES MANAGEMENT.  // Journal of Family Practice;Oct2005 Supplement, Vol. 54, p2 

    This article cites a study that examines the role of basal insulin in type 2 diabetes management. The clinical benefits of initiating insulin therapy early in the course of type 2 diabetes may delay disease progression and simplify diabetes control. In this study, the researchers reported that...

  • Insulin Degludec and Insulin Degludec/Insulin Aspart: A Review of Their Use in the Management of Diabetes Mellitus. Keating, Gillian // Drugs;2013, Vol. 73 Issue 6, p575 

    Insulin degludec (Tresiba) is an ultra-long-acting insulin analogue that is also available as a coformulation with rapid-acting insulin aspart (insulin degludec/insulin aspart) [Ryzodeg]. Insulin degludec has a flat, stable glucose-lowering profile with a duration of action of >42 h, and less...

  • Insulin degludec versus insulin glargine.  // Africa Health;May2011, Vol. 33 Issue 4, p66 

    The article reports on the clinical trials which compares the effectiveness and benefits of using insulin degludec against insulin glargine in adult patients with type 2 diabetes.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics